Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

ClinicalTrials.gov ID: NCT06917911

Public ClinicalTrials.gov record NCT06917911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia (CBF-AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to an antitumor antibiotic drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with cytarabine and daunorubicin may have fewer side effects and be as effective or better than the combination with gemtuzumab ozogamicin in treating patients with core binding factor AML.

Study identification

NCT ID
NCT06917911
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
162 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 59 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 1, 2027
Primary completion
Nov 24, 2027
Completion
Nov 24, 2027
Last update posted
Sep 2, 2026

2027

United States locations

U.S. sites
54
U.S. states
19
U.S. cities
48
Facility City State ZIP Site status
Memorial Hospital West Pembroke Pines Florida 33028 Recruiting
Kootenai Health - Coeur d'Alene Coeur d'Alene Idaho 83814 Recruiting
Kootenai Clinic Cancer Services - Post Falls Post Falls Idaho 83854 Recruiting
Kootenai Clinic Cancer Services - Sandpoint Sandpoint Idaho 83864 Recruiting
Northwestern University Chicago Illinois 60611 Recruiting
University of Kansas Clinical Research Center Fairway Kansas 66205 Recruiting
University of Kansas Cancer Center Kansas City Kansas 66160 Recruiting
University of Kansas Hospital-Indian Creek Campus Overland Park Kansas 66211 Recruiting
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 Recruiting
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 Recruiting
The James Graham Brown Cancer Center at University of Louisville Louisville Kentucky 40202 Recruiting
UofL Health Medical Center Northeast Louisville Kentucky 40245 Recruiting
Tufts Medical Center Boston Massachusetts 02111 Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton Michigan 48114 Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton Michigan 48188 Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea Michigan 48118 Recruiting
Trinity Health Saint Mary Mercy Livonia Hospital Livonia Michigan 48154 Recruiting
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac Michigan 48341 Recruiting
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti Michigan 48197 Recruiting
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus Mississippi 39705 Recruiting
Baptist Cancer Center-Grenada Grenada Mississippi 38901 Recruiting
Baptist Memorial Hospital and Cancer Center-Union County New Albany Mississippi 38652 Recruiting
Baptist Memorial Hospital and Cancer Center-Oxford Oxford Mississippi 38655 Recruiting
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven Mississippi 38671 Recruiting
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters Missouri 63376 Recruiting
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141 Recruiting
Washington University School of Medicine St Louis Missouri 63110 Recruiting
Siteman Cancer Center-South County St Louis Missouri 63129 Recruiting
Siteman Cancer Center at Christian Hospital St Louis Missouri 63136 Recruiting
Billings Clinic Cancer Center Billings Montana 59101 Recruiting
Bozeman Health Deaconess Hospital Bozeman Montana 59715 Recruiting
Benefis Sletten Cancer Institute Great Falls Montana 59405 Recruiting
Community Medical Center Missoula Montana 59804 Recruiting
Nebraska Medicine-Bellevue Bellevue Nebraska 68123 Recruiting
Nebraska Medicine-Village Pointe Omaha Nebraska 68118 Recruiting
University of Nebraska Medical Center Omaha Nebraska 68198 Recruiting
Roswell Park Cancer Institute Buffalo New York 14263 Recruiting
University of Rochester Rochester New York 14642 Recruiting
State University of New York Upstate Medical University Syracuse New York 13210 Recruiting
Montefiore Medical Center - Moses Campus The Bronx New York 10467 Recruiting
Duke University Medical Center Durham North Carolina 27710 Recruiting
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre Pennsylvania 18711 Recruiting
Prisma Health Cancer Institute - Spartanburg Boiling Springs South Carolina 29316 Recruiting
Prisma Health Cancer Institute - Easley Easley South Carolina 29640 Recruiting
Prisma Health Cancer Institute - Butternut Greenville South Carolina 29605 Recruiting
Prisma Health Cancer Institute - Faris Greenville South Carolina 29605 Recruiting
Prisma Health Cancer Institute - Eastside Greenville South Carolina 29615 Recruiting
Prisma Health Cancer Institute - Greer Greer South Carolina 29650 Recruiting
Prisma Health Cancer Institute - Seneca Seneca South Carolina 29672 Recruiting
Baptist Memorial Hospital and Cancer Center-Collierville Collierville Tennessee 38017 Recruiting
Baptist Memorial Hospital and Cancer Center-Memphis Memphis Tennessee 38120 Recruiting
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 Recruiting
Gundersen Lutheran Medical Center La Crosse Wisconsin 54601 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06917911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06917911 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →